Development Of Nanoparticle Encapsulated MiR-107 As An Anti-cancer Therapeutic For Head And Neck Cancer | 12381
Otolaryngology: Open Access
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide with about 600,000 new
cases diagnosed in the last year. The 5-year survival rate of HNSCC has remained stagnant despite advances in the clinical
management of this disease. Understanding the molecular pathways that lead to aggressive HNSCC is crucial to identify new
�druggable� targets for anti-cancer drug development. Our laboratory showed that miR-107 expression is reduced and functions
as a tumor suppressor gene in HNSCC suggesting the potential application of miR-107 as a novel anti-cancer therapeutic. In
this study, we determined the efficiency and efficacy of cationic lipid nanoparticles to deliver pre-miR-107 (NP/pre-miR-107)
in HNSCC cells in vitro and in vivo. NP/pre-miR-107 increased delivery of miR-107 into HNSCC cells by greater than 80,000-
fold compared to free pre-miR-107. Levels of known miR-107 targets, PKCε, CDK6, and HIF1-β, decreased following NP/pre-
miR-107 treatment. Clonogenic survival, cell invasion, and cell migration of HNSCC cells was inhibited with NP/pre-miR-107.
Moreover, NP/pre-miR-107 reduced the cancer initiating cell population and dampened the expression of the core embryonic
stem cell transcription factors, Nanog, Oct3/4, and Sox2. In a pre-clinical mouse model of HNSCC, systemic administration of
NP/pre-miR-107 significantly retarded tumor growth by 45.2% compared to NP/pre-miR-control (p<0.005, n=7). Kaplan-Meir
analysis showed a survival advantage for the NP/pre-miR-107 treatment group (p=0.017). Our results demonstrate that cationic
lipid nanoparticles are an effective carrier approach to deliver therapeutic miRs to HNSCC.
Dr. Pan completed his doctorate in pharmacology at the University of Michigan Medical School in 1999. He completed a postdoctoral fellowship in translational oncology and subsequently joined the faculty at the University of Michigan Medical School as an Assistant Professor to direct a laboratory in translational research focused on head and neck cancer. In 2008, Dr. Pan was recruited to The Ohio State University Medical Center as Associate Professor and Research Director of the Head and Neck Oncology Program. His research is funded by the National Cancer Institute, American Cancer Society, and the Flight Attendant Medical Research Institute.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals